Andò Giuseppe, Morabito Gaetano, de Gregorio Cesare, Trio Olimpia, Saporito Francesco, Oreto Giuseppe
Department of Clinical and Experimental Medicine, Cardiology Section, University of Messina and Azienda Ospedaliera Universitaria Policlinico "Gaetano Martino", Messina, Italy.
Catheter Cardiovasc Interv. 2013 Nov 15;82(6):878-85. doi: 10.1002/ccd.25023. Epub 2013 Jun 27.
In patients undergoing primary percutaneous coronary interventions (PCI) for ST-segment elevation myocardial infarction (STEMI), the occurrence of Contrast-Induced Nephropathy (CIN) has a pronounced impact both on morbidity and mortality. We investigated the variables associated with CIN development in 481 consecutive patients with STEMI undergoing primary PCI and evaluated the predictive value of a 3-variable clinical risk score (the AGEF score) based on age, left ventricular ejection fraction (EF), and estimated glomerular filtration rate (eGFR).
CIN was defined as an absolute increase in serum creatinine ≥0.5 mg/dL or an increase ≥25% from baseline within 72 hr. AGEF score was calculated by adding 1 point to the Age/EF(%) ratio if the eGFR was <60 mL/min per 1.73 m(2) .
Overall, the incidence of CIN was 5.2%. In-hospital mortality was higher in patients with CIN than in those without (16% Vs 1.3%, P = 0.001). At multivariate analysis age (OR 1.06, P = 0.042), eGFR (OR 0.95, P = 0.001), EF (OR 0.94, P = 0.007) and post-procedural TIMI flow grade (OR 0.43, P = 0.045) were independent predictors of CIN. AGEF score was an accurate (OR 5.19, P < 0.001, AUC 0.88) and calibrated (Hosmer-Lemeshow χ(2) = 10.25, P = 0.25) predictor of CIN.
Advanced age, depressed EF, and reduced eGFR are independent predictors of CIN development after primary PCI for STEMI. The preprocedural individual patient risk can be clinically assessed with the calculation of the AGEF score, which is based on such readily available parameters.
在接受直接经皮冠状动脉介入治疗(PCI)的ST段抬高型心肌梗死(STEMI)患者中,造影剂诱导的肾病(CIN)的发生对发病率和死亡率均有显著影响。我们调查了481例连续接受直接PCI的STEMI患者中与CIN发生相关的变量,并评估了基于年龄、左心室射血分数(EF)和估计肾小球滤过率(eGFR)的三变量临床风险评分(AGEF评分)的预测价值。
CIN定义为血清肌酐绝对增加≥0.5mg/dL或在72小时内较基线水平增加≥25%。如果eGFR<60mL/min per 1.73m²,则将年龄/EF(%)比值加1分来计算AGEF评分。
总体而言,CIN的发生率为5.2%。CIN患者的院内死亡率高于无CIN患者(16%对1.3%,P = 0.001)。多因素分析显示,年龄(OR 1.06,P = 0.042)、eGFR(OR 0.95,P = 0.001)、EF(OR 0.94,P = 0.007)和术后TIMI血流分级(OR 0.43,P = 0.045)是CIN的独立预测因素。AGEF评分是CIN的准确预测因素(OR 5.19,P < 0.001,AUC 0.88)且具有校准性(Hosmer-Lemeshow χ² = 10.25,P = 0.25)。
高龄、EF降低和eGFR降低是STEMI患者直接PCI术后CIN发生的独立预测因素。术前可通过计算基于这些易于获得参数的AGEF评分对个体患者风险进行临床评估。